Wednesday, November 6, 2019 – Friday, November 8, 2019

New York Marriott Marquis
1535 Broadway
New York, NY 10036
212-398-1900

Exciting new breakthroughs and rapid changes continue to occur in the management of solid and hematologic malignancies. Just this past year, practice-changing diagnostic, therapeutic, and supportive care strategies have entered clinical practice, and many more are poised to enter the field. The application of optimized testing approaches, locoregional and systemic therapies, including the use of chemotherapies, targeted therapies, immunotherapies, alone and in combination, along with multimodal strategies, continue to drive improved outcomes across multiple lines of care. Critical knowledge, competence, and performance gaps among practitioners must be addressed to ensure that these approaches are effectively and safely integrated into professional practice.

Each year, the Chemotherapy Foundation Symposium^® (CFS^®), brings together more than 1,000 healthcare professionals for 3 days, with the aim of promoting the delivery of evidence-based, state-of-the-art cancer care for both routine and the most challenging clinical scenarios. At the 37th Annual CFS^®, our internationally renowned faculty will provide you with expert insights on the latest developments in cancer therapeutics, offering an unparalleled opportunity to learn how innovative approaches fit into existing treatment paradigms to optimize care and outcomes for your patients with cancer.

As in previous years, this year’s meeting will continue the tradition of the International Congress on Targeted Therapies in Cancer® and the Annual Multidisciplinary Symposium on Head and Neck Cancer® to provide education on cutting edge research that personalizes the treatment of patients with cancers

• Incorporate the latest clinical data and evidence-based strategies into your practice
• Learn experts’ viewpoints on areas of clinical uncertainty
• Network with the top minds in oncology
• 100 Experts. 25 Tumor Types. 3 Days. 1 Meeting. Something for everyone!

This activity is supported by educational grants from AbbVie Inc.; AstraZeneca; Athenex; Celgene Corporation; Daiichi Sankyo, Inc.; Eisai; Exelixis, Inc.; Genomic Health; Incyte Corporation; MacroGenics, Inc.; Novartis Pharmaceuticals Corporation; Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Pfizer; Regeneron; Sanofi Genzyme; Seattle Genetics, Inc.; and Taiho Oncology, Inc.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Physicians’ Education Resource^®, LLC, and Pharmacy Times Continuing Education. Physicians’ Education Resource^®, LLC, is accredited by the ACCME to provide continuing medical education for physicians.

Physicians’ Education Resource^®, LLC, designates this live activity for a maximum of 24.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is approved for 21.75 contact hours (2.175 CEUs) under the ACPE universal activity numbers:
0290-9999-19-196-L01-P
0290-9999-19-197-L01-P
0290-9999-19-198-L01-P

Physicians' Education Resource^®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 24.25 Contact Hours.

This educational activity is directed toward oncologists, hematologists, nurses, nurse practitioners, and pharmacists involved in the treatment/management of patients with cancer. Radiotherapists, immunologists, fellows, physician assistants, researchers, case managers, and other healthcare professionals interested in the treatment of cancer are also invited to attend.

Upon successful completion of this activity, you should be better prepared to:

• Review key testing strategies across tumor types for identification of tumor markers for prognostic/predictive assessment and selection of appropriate treatment
• Recognize practice-changing results to inform improved diagnosis, treatment, and adverse event management across solid and liquid tumors
• Identify ways of translating novel evidence-based treatment strategies using immunotherapeutic, targeted treatment, and chemotherapeutic treatment strategies into clinical practice
• Learn strategies for promoting multidisciplinary best practices in the proactive management of treatment-related toxicities
• Analyze practice-changing evidence presented at major conferences and apply these findings to improve the treatment of patients with cancer